FDA Asks Input on Controlling Nasty New Synthetic Drugs Globally
Published Date: 2/27/2026
Notice
Summary
The FDA is asking for your thoughts on new international rules to control some powerful drugs like N-Pyrrolidino Isotonitazene and MDMB-FUBINACA. These changes could affect drug makers, distributors, and countries worldwide by tightening how these substances are made and shared. Comments are open until March 5, 2026, so jump in now to help shape the U.S. stance before a big UN meeting in March!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Controls aimed at protecting public health
The U.N. Committee recommended adding N‑Pyrrolidino Isotonitazene and N‑Desethyl Etonitazene to Schedule I (1961), retaining coca leaf in Schedule I (1961), and adding MDMB‑FUBINACA to Schedule II (1971). The substances are described in the notice as highly potent, linked to fatal overdoses, and without recognized therapeutic use; the proposals will be considered at the CND meeting March 9–13, 2026.
International manufacturing and distribution limits
The U.N. review recommends international manufacturing and distribution restrictions for several substances, including N‑Pyrrolidino Isotonitazene, N‑Desethyl Etonitazene, MDMB‑FUBINACA, and coca leaf. These recommendations will be considered at the U.N. meeting March 9–13, 2026, and could tighten how makers and distributors handle those substances.
No additional U.S. domestic scheduling needed
The notice states that N‑Pyrrolidino Isotonitazene and N‑Desethyl Etonitazene are already controlled in Schedule I under the U.S. Controlled Substances Act and would not require additional permanent domestic controls if placed in Schedule I internationally. It also states MDMB‑FUBINACA is controlled in Schedule I under the CSA and would not require additional permanent domestic controls if placed in Schedule II internationally, and that domestic scheduling actions for coca leaf will not be necessary regardless of the international vote.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-03913, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on March 31 and April 1, 2026, to review important grant applications. These meetings protect private info and trade secrets while deciding who gets funding for exciting health research. Scientists and applicants should note these dates as they impact which projects get money and support.
Next: 2026-03915, Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of Proposed Rule Change by The Options Clearing Corporation Concerning a Change in Types of Acceptable Collateral and an Update To Mitigate Wrong-Way Risk
The Options Clearing Corporation (OCC) is updating its rules to stop accepting two types of rarely used collateral and to better protect itself from risky situations where things could go wrong at the same time. This change affects the financial firms that use OCC to clear their options trades and helps keep the system safer without changing costs right now. The new rules were proposed in February 2026 and are open for public comments before they take effect.